Peer Reviewed
Drug update
Tapentadol: a new analgesic among the opioids
Abstract
Tapentadol offers equianalgesic effects to conventional opioids with reduced gastrointestinal adverse effects and possibly a lower abuse potential. It is a representative of a new class of analgesics relying on the analgesic synergy between mu-receptor agonism and noradrenaline reuptake inhibition.
Key Points
Tapentadol is a recently registered analgesic for the treatment of chronic moderate to severe pain that relies on the synergy between mu-receptor agonism and noradrenaline reuptake inhibition to provide pain relief. It is not really a new opioid but a representative of a new class of analgesics relying on this analgesic synergy.
Get full access
Buy this article
Single article purchases are temporarily unavailable due to site maintenance.
If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.
Thank you for your patience and understanding.
Already a subscriber? Login here.